Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Gross margin
Zoetis Inc.'s gross margin over the twelve months to 30 June 2026 was 71.7%, down 0.2 percentage points from fiscal 2025 (71.8%). Over the past ten years it has ranged from 63.5% (fiscal 2015) to 71.8% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 53.9% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 71.8% | 1.22 |
| FY2024 | 70.6% | 0.59 |
| FY2023 | 70.0% | 0.40 |
| FY2022 | 69.6% | (0.75) |
| FY2021 | 70.4% | 1.20 |
| FY2020 | 69.2% | 1.00 |
| FY2019 | 68.2% | 0.99 |
| FY2018 | 67.2% | 0.64 |
| FY2017 | 66.6% | 0.63 |
| FY2016 | 65.9% | 2.39 |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 72.7% | 1.07 |
| Mar 2026 | 71.7% | 0.93 |
| Dec 2025 | 70.7% | (0.81) |
| Sep 2025 | 71.5% | (1.62) |
| 42 more quarters | Free account |
Against its own ten years
Low 63.5%
High 71.8%
Ten-year median
69.2%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 97.9% |
| UTHR United Therapeutics Corporation compare | 86.1% |
| ZTS Zoetis Inc. | 71.7% |
| TAK Takeda Pharmaceutical Co. compare | 65.9% |
| HLN Haleon PLC Sponsored ADR compare | 62.2% |
| ELAN Elanco Animal Health Incorporated compare | 55.4% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 52.5% |
| RDY Dr. Reddy's Laboratories Ltd compare | 50.0% |
| VTRS Viatris Inc. compare | 34.8% |
| Drug Manufacturers Specialty & Generic industry median | 53.9% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement